Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.114182 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Enriqueta Felip und 22 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain. Electronic address: efelip@…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, ErbB Receptors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Novartis AG.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain. Electronic address: efelip@vhio.net.
- Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy.
- National University Cancer Institute Singapore, Singapore.
- Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
- Peter MacCallum Cancer Centre, Melbourne, Australia.
- National Cancer Centre, Duke-NUS Medical School, Singapore.
Förderung
- Novartis AG
Zitieren
APA
Felip, E., Metro, G., Soo, R. A., Wolf, J., Solomon, B. J., Tan, D. S., Ardizzoni, A., Lee, D. H., Sequist, L. V., Barlesi, F., Ponce-Aix, S., Abreu, D. R., Campelo, M. R. G., Sprauten, M., Djentuh, L. O., Smith, N., Jary, A., Belli, R., Glaser, S., …, & Yang, J. C. (2024). Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114182
Vancouver
Felip E, Metro G, Soo RA, Wolf J, Solomon BJ, Tan DS, et al. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114182
BibTeX
@article{Felip2024,
author = {Felip, Enriqueta and Metro, Giulio and Soo, Ross A and Wolf, Jürgen and Solomon, Benjamin J and Tan, Daniel Sw and Ardizzoni, Andrea and Lee, Dae Ho and Sequist, Lecia V and Barlesi, Fabrice and Ponce-Aix, Santiago and Abreu, Delvys Rodriguez and Campelo, Maria Rosario Garcia and Sprauten, Mette and Djentuh, Leslie O'Sullivan and Smith, Nathalie and Jary, Aline and Belli, Riccardo and Glaser, Sabine and Zou, Mike and Cui, Xiaoming and Giovannini, Monica and Yang, James Chih-Hsin},
title = {Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.114182}
}
EUVIMED